Similar articles

Abstract: Objective: The aim of our study was to perform a systematic review and meta-analysis of the efficacy of short-term protocols for Helicobacter pylori eradication and to review the safety and adverse profiles of these eradication protocols. Methods: Literatures were located through electronic searches by PubMed, Medline, ISI Web of Knowledge, and Cochrane Library using the relevant terms. Abstracts of important meetings were searched manually in some journal supplements. Additional bibliographies were identified from the reference lists of identified studies. Three independent reviewers systemically identified randomized controlled trials (RCTs) comparing short-duration protocols vs. 7-d proton pump inhibitor (PPI)-based triple protocols, as well as studies reporting eradication rates of short-duration protocols for H. pylori. Summary effect size was calculated as relative risk (RR) and 95% confidence intervals (CI) using Review Manager 4.2, and P<0.05 was defined as statistically significant in all analyses. Results: Among 90 abstracts retrieved, 15 studies were analyzed, including a total of 30 treatment regimens with 1856 subjects. Mean intention-to-treat (ITT) cure rates of 63.2% and 81.3% were achieved with short-term protocols and 7-d PPI-containing protocols, respectively. Per-protocol (PP)-based overall cure rates were 66.6% and 86.1%, respectively. short-term therapy was inferior to 7-d triple regimen (P<0.00001). After sub-analysis, however, comparing the effects of ≥3-d protocols and 7-d triple protocols, the cumulative ITT RR was 0.95 (P=0.26), and PP RR was 0.95 (P=0.10), without significant heterogeneity. Moreover, slightly fewer adverse-effects were found in short-term protocols. Conclusions: Although more economical, short-duration protocols are inferior to 7-d PPI-based triple protocols with regarding to eradication rate of H. pylori. Protocols of more than 3 d, however, may be equivalent to 7-d protocols.

[1]Ammon, S., Treiber, G., Kees, F., Klotz, U., 2000. Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. Aliment. Pharmacol. Ther., 14(6):759-766.

[2]Canter, P.H., Wider, B., Ernst, E., 2007. The antioxidant vitamins A, C, E and selenium in the treatment of arthritis: a systematic review of randomized clinical trials. Rheumatology (Oxford), 46(8):1223-1233.

[3]Catalano, F., Branciforte, G., Bentivegna, C., Brogna, A., 1997. Duodenal ulcer and functional dyspepsia: different susceptibility of Helicobacter pylori to eradicating therapy. Helicobacter, 2(2):106.

[4]Chu, K.M., Choi, H.K., Tuen, H.H., Law, S.Y., Branicki, F.J., Wong, J., 1998. A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori. Am. J. Gastroenterol., 93(9):1436-1442.

[5]Fischbach, L.A., Goodman, K.J., Feldman, M., Aragaki, C., 2002. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int. J. Epidemiol., 31(1):128-139.

[6]Fuccio, L., Minardi, M.E., Zagari, R.M., Grilli, D., Magrini, N., Bazzoli, F., 2007. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann. Intern. Med., 147(8):553-562.

[7]Gambaro, C., Bilardi, C., Dulbecco, P., Iiritano, E., Zentilin, P., Mansia, C., Usai, P., Vigneri, S., Savarino, V., 2003. Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. Dig. Liver Dis., 35(11):763-767.

[8]Giannini, E.G., Bilardi, C., Dulbecco, P., Mamone, M., Santi, M.L., Testa, R., Mansi, C., Savarino, V., 2006. Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. J. Clin. Gastroenterol., 40(6):515-520.

[9]Gisbert, J.P., Morena, F., 2006. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment. Pharmacol. Ther., 23(1):35-44.

[10]Gisbert, J.P., Gonzalez, L., Calvet, X., 2005. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter, 10(3):157-171.

[11]Graham, D.Y., Lu, H., Yamaoka, Y., 2007. A report card to grade Helicobacter pylori therapy. Helicobacter, 12(4):275-278.

[12]Grimley, C.E., Penny, A., O'sullivan, M., Shebani, M., Lismore, J.R., Cross, R., Illing, R.C., Loft, D.E., Nwokolo, C.U., 1999. Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. Aliment. Pharmacol. Ther., 13(7):869-873.

[13]Huo, X.H., Chu, J.K., Yang, X.F., Wang, J., Zhang, L.J., Ma, J.C., Yu, J., 2006. Efficacy of one-day quadruple therapy for H. pylori infection in Chinese patients. World. J. Gastroenterol., 12(19):3105-3107.

[14]Isomoto, H., Furusu, H., Morikawa, T., Mizuta, Y., Nishiyama, T., Omagari, K., Murase, K., Inoue, K., Murata, I., Kohno, S., 2000. 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. Aliment. Pharmacol. Ther., 14(12):1619-1623.

[15]Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J., Gavaghan, D.J., McQuay, H.J., 1996. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials, 17(1):1-12.

[16]Jafri, N.S., Hornung, C.A., Howden, C.W., 2008. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann. Intern. Med., 148(12):923-931.

[17]Kim, B.G., Lee, D.H., Ye, B.D., Lee, K.H., Kim, B.W., Kim, S.G., Kim, S.W., Kim, S.K., Kim, J.J., Kim, H.Y., et al., 2007. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter, 12(1):31-35.

[18]Lai, J.Y., de Boer, W.A., Driessen, W.M., Geuskens, L.M., 1996. Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy. Aliment. Pharmacol. Ther., 10(4):645-650.

[19]Lara, L.F., Cisneros, G., Gurney, M., van Ness, M., Jarjoura, D., Moauro, B., Polen, A., Rutecki, G., Whittier, F., 2003. One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection. Arch. Intern. Med., 163(17):2079-2084.

[20]Li, Y.M., Li, L., Yu, C.H., Liu, Y.S., Xu, C.F., 2008. A systematic review and meta-analysis of the treatment for Barrett’s esophagus. Dig. Dis. Sci., 53(11):2837-2846.

[21]Malekzadeh, R., Merat, S., Derakhshan, M.H., Siavoshi, F., Yazdanbod, A., Mikaeli, J., Sotoudemanesh, R., Sotoudeh, M., Farahvash, M.J., Nasseri-Moghaddam, S., et al., 2003. Low Helicobacter pylori eradication rates with 4- and 7-day regimens in an Iranian population. J. Gastroenterol. Hepatol., 18(1):13-17.

[22]Misiewicz, J.J., Harris, A.W., Bardhan, K.D., Levi, S., O'Morain, C., Cooper, B.T., Kerr, G.D., Dixon, M.F., Langworthy, H., Piper, D., 1997. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut., 41(6):735-739.

[23]Moshkowitz, M., Konikoff, F.M., Arber, N., Peled, Y., Santo, M., Bujanover, Y., Gilat, T., 1994. Seasonal variation in the frequency of Helicobacter pylori infection: a possible cause of the seasonal occurrence of peptic ulcer disease. Am. J. Gastroenterol., 89(5):731-733.

[24]Moshkowitz, M., Brill, S., Konikoff, F.M., Reif, S., Arber, N., Halpern, Z., 1999. The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia. J. Am. Geriatr. Soc., 47(6):720-722.

[25]Nagahara, A., Miwa, H., Yamada, T., Kurosawa, A., Ohkura, R., Sato, N., 2001. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. Aliment. Pharmacol. Ther., 15(3):417-421.

[26]Namiot, D.B., Leszczyńska, K., Namiot, Z., Kurylonek, A.J., Kemona, A., 2008. Smoking and drinking habits are important predictors of Helicobacter pylori eradication. Adv. Med. Sci., 53(2):310-315.

[27]Namiot, Z., Namiot, D.B., Kemona, A., Gołebiewska, M., Bucki, R., 2000. The effect of cigarette smoking and alcohol consumption on efficacy of Helicobacter pylori eradication. Pol. Arch. Med. Wewn., 104(3):569-574.

[28]Ogura, K., Yoshida, H., Maeda, S., Yamaji, Y., Kawabe, T., Okamoto, M., Shiratori, Y., Omata, M., 2001. Clarithromycin-based triple therapy for non-resistant Helicobacter pylori infection. How long should it be given? Scand. J. Gastroenterol., 36(6):584-588.

[29]Pieramico, O., Zanetti, M.V., Innerhofer, M., 1998. Three-days and seven-days triple therapy with clarithromycin or azithromycin for cure of Helicobacter pylori infection. Gastroenterology, 114(4):A258-A259.

[30]Savarino, V., Zentilin, P., Bisso, G., Pivari, M., Bilardi, C., Biagini, R., Mele, M.R., Mansi, C., Termini, R., Vigneri, S., et al., 1999. Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. Aliment. Pharmacol. Ther., 13(1):43-47.

[31]Scuderi, G., Celi, D., Romagnolo, M., Lupi, A., Alecci, L., Dramissino, I., Battaglino, D., Massari, S., Hoffer, P., 2000. Helicobacter pylori: use of a stool antigen detection test and a six-day triple therapy. Dig. Liver Dis., 32(1):71-73.

[32]Sugimoto, M., Furuta, T., Shirai, N., Kodaira, C., Nishino, M., Yamade, M., Ikuma, M., Watanabe, H., Ohashi, K., Hishida, A., et al., 2007. Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert. Opin. Pharmacother., 8(16):2701-2717.

[33]Treiber, G., 1996. The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am. J. Gastroenterol., 91(2):246-257.

[34]Treiber, G., 2000. Treating H. pylori shorter than one week: a real future perspective? Z. Gastroenterol., 38(9):807-812.

[35]Treiber, G., Ammon, S., Schneider, E., Klotz, U., 1998. Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter, 3(1):54-58.

[36]Trevisani, L., Sartori, S., Caselli, M., Ruina, M., Verdianelli, G., Abbasciano, V., 1998. A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. Am. J. Gastroenterol., 93(3):390-393.

[37]Tucci, A., Corinaldesi, R., Stanghellini, V., Paparo, G.F., Gasperoni, S., Biasco, G., Varoli, O., Ricci-Maccarini, M., Barbara, L., 1993. One-day therapy for treatment of Helicobacter pylori infection. Dig. Dis. Sci., 38(9):1670-1673.

[38]Tucci, A., Poli, L., Paparo, G.F., Bocus, P., Togliani, T., Mazzoni, C., Orcioni, G.F., Agosti, R., Grigioni, W.F., Sottili, S., et al., 1998. Weekend therapy for the treatment of Helicobacter pylori infection. Am. J. Gastroenterol., 93(5):737-742.

[39]Vakil, N., Schwartz, H.J., Lanza, F.L., Nardi, L., Hahne, W., Barth, J., 2002. A prospective, controlled, randomized trial of 3-, 7-, and 10-day rabeprazole-based triple therapy for H. pylori eradication in the USA. Gastroenterology, 122(Suppl. 4):A65.

[40]Vergara, M., Vallve, M., Gisbert, J.P., Calvet, X., 2003. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther., 18(6):647-654.

[41]Wang, C., Yuan, Y., Hunt, R.H., 2007. The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis. Am. J. Gastroenterol., 102(8):1789-1798.

[42]Wang, F., Wang, X.Y., Jia, Y., Shen, S.R., Xu, C.X., Tang, W.L., Liu, S.J., Chen, X., 2004. Five-day rabeprazole-based triple therapy for Helicobacter pylori infection. J. Central South Univ. (Med. Sci.), 29(5):589-591 (in Chinese).

[43]Wang, L., Li, Y.M., Li, L., 2009. Meta-analysis of randomized and controlled treatment trials for achalasia. Dig. Dis. Sci., 54(11):2303-2311.

[44]Wermeille, J., Cunningham, M., Armenian, B., Zelger, G., Buri, P., Merki, H., Hadengue, A., 1999. Failure of a 1-day high-dose quadruple therapy for cure of Helicobacter pylori infection. Aliment. Pharmacol. Ther., 13(2):173-177.

[45]Wong, B.C., Wong, W.M., Yee, Y.K., Hung, W.K., Yip, A.W., Szeto, M.L., Li, K.F., Lau, P., Fung, F.M., Tong, T.S., et al., 2001a. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther., 15(12):1959-1965.

[46]Wong, B.C., Wang, W.H., Wong, W.M., Lau, G.K., Fung, F.M., Kung, N.N., Chu, K.M., Lai, K.C., Hu, W.H., Hu, F.L., et al., 2001b. Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study. Aliment. Pharmacol. Ther., 15(6):843-849.

[47]Yang, K.C., Wang, G.M., Chen, J.H., Che, T.J., Lee, S.C., 2003. Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. J. Formos. Med. Assoc., 102(12):857-862.

[48]Zhang, L., Shen, L., Ma, J.L., Pan, K.F., Liu, W.D., Li, J., Xiao, S.D., Lin, S.R., Classen, M., You, W.C., 2006. Eradication of H. pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy. World J. Gastroenterol., 12(24):3915-3918.

[49]Zheng, Q., Pan, Y., Zhang, L., Xiao, S.D., 2005. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection. Chin. J. Dig. Dis., 6(4):202-205.

[50]Zimmermann, J., Amon, R., Beeri, R., Keret, D., Lysy, J., Ligumski, M., Gonzalez, J., Fich, A., Ackerman, Z., Goldin, E., 1992. Seasonal fluctuation in acute upper gastrointestinal bleeding: lack of effect of non-steroidal anti-inflammatory drugs. Am. J. Gastroenterol., 87(11):1587-1590.